MSFT   183.92 (-0.54%)
GOOGL   1,439.67 (-0.18%)
AMZN   2,469.15 (-0.13%)
NVDA   351.07 (-0.55%)
GE   7.29 (+3.41%)
TSLA   890.19 (+1.00%)
T   31.37 (+1.23%)
ACB   14.45 (-0.55%)
F   6.09 (+3.05%)
GILD   74.10 (+1.15%)
DIS   120.72 (+1.66%)
BAC   25.89 (+4.23%)
MSFT   183.92 (-0.54%)
GOOGL   1,439.67 (-0.18%)
AMZN   2,469.15 (-0.13%)
NVDA   351.07 (-0.55%)
GE   7.29 (+3.41%)
TSLA   890.19 (+1.00%)
T   31.37 (+1.23%)
ACB   14.45 (-0.55%)
F   6.09 (+3.05%)
GILD   74.10 (+1.15%)
DIS   120.72 (+1.66%)
BAC   25.89 (+4.23%)
MSFT   183.92 (-0.54%)
GOOGL   1,439.67 (-0.18%)
AMZN   2,469.15 (-0.13%)
NVDA   351.07 (-0.55%)
GE   7.29 (+3.41%)
TSLA   890.19 (+1.00%)
T   31.37 (+1.23%)
ACB   14.45 (-0.55%)
F   6.09 (+3.05%)
GILD   74.10 (+1.15%)
DIS   120.72 (+1.66%)
BAC   25.89 (+4.23%)
MSFT   183.92 (-0.54%)
GOOGL   1,439.67 (-0.18%)
AMZN   2,469.15 (-0.13%)
NVDA   351.07 (-0.55%)
GE   7.29 (+3.41%)
TSLA   890.19 (+1.00%)
T   31.37 (+1.23%)
ACB   14.45 (-0.55%)
F   6.09 (+3.05%)
GILD   74.10 (+1.15%)
DIS   120.72 (+1.66%)
BAC   25.89 (+4.23%)
Log in

NASDAQ:AXGNAxoGen Stock Price, Forecast & News

$10.07
+0.22 (+2.23 %)
(As of 06/3/2020 10:49 AM ET)
Add
Compare
Today's Range
$9.73
Now: $10.07
$10.25
50-Day Range
$7.35
MA: $8.60
$10.12
52-Week Range
$7.16
Now: $10.07
$22.94
Volume44,013 shs
Average Volume520,274 shs
Market Capitalization$400.38 million
P/E RatioN/A
Dividend YieldN/A
Beta0.43
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More
AxoGen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$106.71 million
Book Value$3.35 per share

Profitability

Net Income$-29,140,000.00

Miscellaneous

EmployeesN/A
Market Cap$400.38 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

How has AxoGen's stock been impacted by COVID-19 (Coronavirus)?

AxoGen's stock was trading at $10.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXGN stock has decreased by 5.6% and is now trading at $10.10. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AxoGen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AxoGen.

When is AxoGen's next earnings date?

AxoGen is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for AxoGen.

How were AxoGen's earnings last quarter?

AxoGen, Inc (NASDAQ:AXGN) posted its quarterly earnings data on Wednesday, May, 6th. The medical equipment provider reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.04. The medical equipment provider had revenue of $24.26 million for the quarter, compared to the consensus estimate of $24.30 million. AxoGen had a negative return on equity of 20.04% and a negative net margin of 25.84%. View AxoGen's earnings history.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its first quarter 2020 Pre-Market earnings guidance on Thursday, April, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $24.3-24.3 million, compared to the consensus revenue estimate of $27.06 million.

What price target have analysts set for AXGN?

5 equities research analysts have issued 1-year price targets for AxoGen's stock. Their forecasts range from $12.00 to $28.00. On average, they expect AxoGen's share price to reach $20.50 in the next year. This suggests a possible upside of 103.0% from the stock's current price. View analysts' price targets for AxoGen.

Has AxoGen been receiving favorable news coverage?

Headlines about AXGN stock have been trending somewhat positive on Wednesday, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AxoGen earned a daily sentiment score of 0.6 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutAxoGen.

Are investors shorting AxoGen?

AxoGen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,740,000 shares, an increase of 24.3% from the April 30th total of 1,400,000 shares. Based on an average daily trading volume, of 559,600 shares, the days-to-cover ratio is presently 3.1 days. Currently, 4.8% of the company's shares are sold short. View AxoGen's Current Options Chain.

Who are some of AxoGen's key competitors?

What other stocks do shareholders of AxoGen own?

Who are AxoGen's key executives?

AxoGen's management team includes the following people:
  • Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)
  • Mr. Peter J. Mariani, Chief Financial Officer (Age 55)
  • Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)
  • Mr. Michael Donovan, VP of Operations (Age 54)
  • Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel.

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (15.92%), BlackRock Inc. (7.06%), Baillie Gifford & Co. (2.62%), William Blair Investment Management LLC (2.61%), Janus Henderson Group PLC (2.47%) and State Street Corp (2.39%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Michael Patrick Donovan and Quentin S Blackford. View institutional ownership trends for AxoGen.

Which major investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Portolan Capital Management LLC, State Street Corp, Bank of New York Mellon Corp, Soleus Capital Management L.P., Morgan Stanley, Spark Investment Management LLC, Parametric Portfolio Associates LLC, and Victory Capital Management Inc.. View insider buying and selling activity for AxoGen.

Which major investors are buying AxoGen stock?

AXGN stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, ArrowMark Colorado Holdings LLC, JPMorgan Chase & Co., William Blair Investment Management LLC, Deutsche Bank AG, Peregrine Capital Management LLC, Geode Capital Management LLC, and Squarepoint Ops LLC. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej, and Quentin S Blackford. View insider buying and selling activity for AxoGen.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $10.10.

How big of a company is AxoGen?

AxoGen has a market capitalization of $401.58 million and generates $106.71 million in revenue each year. The medical equipment provider earns $-29,140,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

What is AxoGen's official website?

The official website for AxoGen is www.axogeninc.com.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.